Savic, Radojka M.
Novakovic, Ana M.
Ekblom, Marianne
Munafo, Alain
Karlsson, Mats O.
Clinical trials referenced in this document:
Documents that mention this clinical trial
016 Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension
https://doi.org/10.1136/jnnp-2022-abn.55
024 CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets
https://doi.org/10.1136/jnnp-2022-abn.63
Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
https://doi.org/10.1007/s40262-017-0516-6
015 Reduced risk of secondary progressive multiple sclerosis by treatment with clad- ribine tablets: CLARITY study analysis
https://doi.org/10.1136/jnnp-2022-abn.54
022 Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data
https://doi.org/10.1136/jnnp-2022-abn.61
Funding for this research was provided by:
MerckSerono
Article History
First Online: 2 March 2017
Compliance with Ethical Standards
:
: This study was supported by Merck Serono S.A., Geneva, Switzerland, an affiliation of Merck KGaA, Darmstadt, Germany.
: Dr. Savic and Dr. Karlsson were/are, respectively, employees of the Uppsala University, which received financial support for performing this analysis. Mrs Novakovic has received financial support from Merck Serono for attending a symposia. Dr. Ekblom was an employee of Merck Serono S.A., Geneva, Switzerland, an affiliation of Merck KGaA, Darmstadt, Germany, at the time of the analysis. Dr. Munafo is an employee of Merck Institute for Pharmacometrics, Lausanne, Switzerland.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the studies.